Background context Advances in the field of stem cell technology have stimulated the
development and increased use of allogenic bone grafts containing live mesenchymal stem …

While liver transplantation remains the sole treatment option for patients with end-stage liver
disease, there are numerous limitations to liver transplantation including the scarcity of …

Use of mesenchymal stem cells (MSCs) has emerged as a potential new treatment for
various diseases but has generated marginally successful results. A consistent finding of …

Background Renal ischemia/reperfusion injury (rIRI) is one of the major causes of AKI.
Although animal models are suitable for investigating systemic symptoms of AKI, they are …

Ischemia-reperfusion (IR) triggers tissue injury by activating innate immunity, for example,
via TLR2 and TLR4. Surprisingly, TLR signaling in intrinsic renal cells predominates in …

A major limitation in the development of cellular therapies using human mesenchymal stem
cells (hMSCs) is cell survival post-transplantation. In this study, we challenged the current …

Local tissue ischemia is a prime cause responsible for the massive cell death in tissue-
engineered (TE) constructs observed postimplantation. To assess the impact of ischemia on …

Heart disease is the leading cause of mortality in western countries. Apart from congenital
and anatomical alterations, ischemia is the most common agent causing myocardial …

BACKGROUND AND PURPOSE Peroxisome proliferator‐activated receptors (PPARs) are
ligand‐activated transcription factors, and three subtypes (α, β and γ) have been identified …

Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands constitute important insulin
sensitizers that have already been used for the treatment of human metabolic disorders …